Radionuclide molecular imaging using affibody molecules

Current Pharmaceutical Biotechnology

Volumn 11, Issue 6, 2010, Pages 581-589

  Ahlgren, Sara ^a   Tolmachev, Vladimir ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecules; EGFR; HER2; Molecular imaging; Radionuclide; Scaffold proteins; Targeting

Indexed keywords

AFFIBODY MOLECULE; COPPER 64; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORINE 18; GALLIUM 68; INDIUM 111; IODINE 124; RADIOISOTOPE; SCAFFOLD PROTEIN; TECHNETIUM 99M; TRASTUZUMAB; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; HYBRID PROTEIN; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER THERAPY; IN VIVO STUDY; MOLECULAR IMAGING; MOLECULAR RECOGNITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PH; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; HUMAN; IMAGE ENHANCEMENT; ISOTOPE LABELING; METHODOLOGY; NEOPLASM;

HUMANS; IMAGE ENHANCEMENT; ISOTOPE LABELING; MOLECULAR IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECOMBINANT FUSION PROTEINS;

EID: 79952118497     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110792246609     Document Type: Article

References (84)

1. Zafir-Lavie, I.; Michaeli, Y; Reiter Y. Novel antibodies as anticancer agents. Oncogene. 2007, 26(25), 3714-3733.
2. Hartmann, J.T.; Haap, M.; Kopp, H.G.; Lipp, H.P. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr. Drug. Metab., 2009, 10(5), 470-481.
3. Kelloff, G.J.; Krohn, K.A.; Larson, S.M.; Weissleder, R.; Mankoff, D.A.; Hoffman, J.M.; Link, J.M.; Guyton, K.Z.; Eckelman, W.C.; Scher, H.I.; O'Shaughnessy, J.; Cheson, B.D.; Sigman, C.C.; Tatum, J.L.; Mills, G.Q.; Sullivan, D.C.;Woodcock J. The progress and promise of molecular imaging probes in oncologic drug development. Clin. Cancer Res. 2005, 11(22), 7967-7985.
4. McLarty, K; Reilly, R.M. Molecular imaging as a tool for personalized and targeted anticancer therapy. Clin. Pharmacol. Ther. 2007, 81(3), 420-424.
5. Britz-Cunningham, S.H.; Adelstein, S.J. Molecular targeting with radionuclides: state of the science. J. Nucl. Med. 2003, 44(12), 1945-1961.
6. Goldenberg, D.M.; Nabi, H.A. Breast cancer imaging with radiolabeled antibodies. Semin. Nucl. Med. 1999, 29(1),41-48.
7. Neves, A.A.; Brindle, K.M. Assessing responses to cancer therapy using molecular imaging. Biochim. Biophys. Acta. 2006, 1766(2),242-261.
8. Kenanova, V.; Wu AM. Tailoring antibodies for radionuclide delivery. Expert Opin. Drug. Deliv. 2006, 3(1), 53-70.
9. Yokota, T.; Milenic, D.E.; Whitlow, M.; Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992, 52(12), 3402-3408.
10. Heppeler, A.; Froidevaux, S.; Eberle, A.N.; Maecke, H.R. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr. Med. Chem. 2000, 7(9),971-994.
11. Grönwall, C.; Ståhl, S. Engineered affinity proteins--generation and applications. J. Biotechnol., 2009, 140(3-4), 254-269.
12. Grabulovski, D.; Kaspar, M; Neri, D. A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J. Biol. Chem., 2007, 282(5), 3196-3204.
13. Jiang, L.; Kimura, R.H.; Miao, Z.; Silverman, A.P.; Ren, G.; Liu, H.; Li, P.; Gambhir, S.S.; Cochran, J.R.; Cheng Z. Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin. J. Nucl. Med., 2010, 51(2), 251-258.
14. Zahnd, C.; Kawe, M.; Stumpp, M.T.; de Pasquale, C.; Tamaskovic, R.; Nagy-Davidescu, G.; Dreier, B.; Schibli, R.; Binz, H.K.; Waibel, R.; Plückthun, A. Efficient tumor targeting with highaffinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res. 2010, 70(4), 1595-1605.
15. Nilsson, J.; Stahl, S.; Lundeberg, J.; Uhlen, M.; Nygren, P.A. Affinity fusion strategies for detection, purification and immobilization of recombinant proteins. Protein Exp. Purif. 1997, 11(1), 1-16.
16. Nygren, P.A. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J., 2008, 275(11), 2668-2676.
17. Nord, K.; Nilsson, J.; Nilsson, B.; Uhlen, M.; Nygren, P.A. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng. 1995, 8(6), 601-608.
18. Nord, K.; Gunneriussin, E.; Ringdahl, J.; Stahl, S.; Uhlen, M.; Nygren, P.A. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat. Biotechnol. 1997, 15(8), 772-777.
19. Wikman, M.; Steffen, A.C.; Gunneriusson, E.; Tolmachev, V.; Adams, G.P.; Carlsson, J.; Ståhl, S. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng. Des. Sel. 2004, 17(5), 455-462.
20. Friedman, M.; Nordberg, E.; Höidén-Guthenberg, I.; Brismar, H.; Adams, G.P.; Nilsson, F.Y.; Carlsson, J.; Ståhl, S. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng. Des. Sel., 2007, 20(4), 189-199.
21. Renberg, B.; Nordin, J.; Merca, A.; Uhlén, M.; Feldwisch, J.; Nygren, PA.; Karlström, AE. Affibody molecules in protein capture microarrays: evaluation of multidomain ligands and different detection formats. J. Proteome Res. 2007, 6(1),171-179.
22. Rönnmark, J.; Grönlund, H.; Uhlén, M.; Nygren, P.A. Human immunoglobulin A (IgA)-specific ligands from combinatorial engineering of protein A. Eur. J. Biochem. 2002, 269(11), 2647-2655.
23. Grönwall, C.; Jonsson, A.; Lindström, S.; Gunneriusson, E.; Ståhl, S.; Herne N. Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. J. Biotechnol. 2007, 128(1), 162-183.
24. Wikman, M.; Rowcliffe, E.; Friedman, M.; Henning, P.; Lindholm, L.; Olofsson, S.; Ståhl, S. Selection and characterization of an HIV-1 gp120-binding affibody ligand. Biotechnol. Appl. Biochem. 2006, 45(Pt 2), 93-105.
25. Sandström, K.; Xu, Z.; Forsberg, G.;Nygren, P.A. Inhibition of the CD28-CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering. Protein Eng. 2003, 16(9), 691-697.
26. Gunneriusson, E.; Nord, K.; Uhlén, M.; Nygren, P. Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. Protein Eng., 1999, 12(10),873-878.
27. Nord, K.; Nord, O.; Uhlén, M.; Kelley, B.; Ljungqvist, C.; Nygren P.A. Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A. Eur. J. Biochem. 2001, 268(15), 4269-4277.
28. Orlova, A.; Magnusson, M.; Eriksson, T.L.; Nilsson, M.; Larsson, B.; Höidén-Guthenberg, I.; Widström, C.; Carlsson, J.; Tolmachev, V.; Ståhl, S.; Nilsson, F.Y. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res., 2006, 66(8), 4339-4348.
29. Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer, 2005, 5(5),341-354.
30. Yarden, Y.; Sliwkowski, M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol., 2001, 2(2), 127-137.
31. Baselga, J.; Perez, E.A.; Pienkowski, T.; Bell, R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist, 2006, 11 (Suppl 1), 4-12.
32. Scaltriti, M.; Baselga, J. The epidermal growth factor receptor pathway: a model for y. Clin. Cancer. Res., 2006, 12(18), 5268-5272.
33. Nahta, R.; Esteva, F.J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006, 8(6),215.
34. Pal, S.K.; Pegram, M. HER2 targeted therapy in breast cancer. beyond Herceptin. Rev. Endocr. Metab. Disord. 2007, 8(3), 269-277.
35. Rasmussen, B.B.; Andersson, M.; Christensen, I.J.; Møller, S. Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic variables. Acta Oncol. 2008, 47(4), 784-788.
36. Rydén, L.; Haglund, M.; Bendahl, P.O.; Hatschek, T.; Kolaric, A.; Kovács, A.; Olsson, A.; Olsson, H.; Strand, C.; Fernö, M, Swedish Her2 Analysis Group. Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer: a national survey performed at pathology departments in Sweden. Acta Oncol. 2009, 48(6), 860-866.
37. Bast, R.C. Jr.; Ravdin, P.: Hayes, D.F.; Bates, S.; Fritsche; H. Jr; Jessup, J.M.; Kemeny, N.; Locker, G.Y.; Mennel, R.G.; Somerfield, M. R American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol., 2001, 19 (6),1865-1878.
38. Molina, R.; Barak, V.; van Dalen, A.; Duffy, M.J.; Einarsson, R.; Gion, M.; Goike, H.; Lamerz, R.; Nap, M.; Sölétormos, G.; Stieber, P. Tumor markers in breast cancer-European Group on Tumor Markers recommendations. Tumour Biol. 2005, 26(6), 281-293.
39. Perez, E.A.; Suman, V.J.; Davidson, N.E.; Martino, S.; Kaufman, P.A.; Lingle, W.L.; Flynn, P.J.; Ingle, J.N.; Visscher, D.; Jenkins, R.B. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J. Clin. Oncol. 2006, 24(19), 3032-3038.
40. Steffen, A.C.; Wikman, M.; Tolmachev, V.; Adams, G.P.; Nilsson, F.Y.; Ståhl, S.; Carlsson, J. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm. 2005, 20(3), 239-248.
41. Steffen, A.C.; Orlova, A.; Wikman, M.; Nilsson, F.Y.; Ståhl, S.; Adams, G.P.; Tolmachev, V.; Carlsson J. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur. J. Nucl. Med. Mol. Imaging. 2006, 33(6), 631-638.
42. Orlova, A.; Nilsson, F.Y.; Wikman, M.; Widström, C.; Ståhl, S.; Carlsson, J.; Tolmachev, V. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for singlephoton imaging of HER2 expression in tumors. J. Nucl. Med., 2006, 47(3), 512-519.
43. Tolmachev, V.; Mume, E.; Sjöberg, S.; Frejd, F.Y.; Orlova, A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur. J. Nucl. Med. Mol. Imaging. 2009, 36(4), 692-701.
44. Cheng, Z.; De Jesus, O.P.; Namavari, M.; De, A.; Levi, J.; Webster, J.M.; Zhang, R.; Lee, B.; Syud, F.A.; Gambhir, S.S. Smallanimal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J. Nucl. Med. 2008, 49(5), 804-813.
45. Cheng, Z.; De Jesus, O.P.; Kramer, D.J.; De, A.; Webster, J.M.; Gheysens, O.; Levi, J.; Namavari, M.; Wang, S.; Park, J.M.; Zhang, R; Liu. H.; Lee, B.; Syud, F.A.; Gambhir, S.S. (64)Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol. Imaging. Biol., 2009, 12(3)316-324.
46. Tolmachev, V.; Friedman, M.; Sandström, M.; Eriksson, T.L.; Rosik, D.; Hodik, M.; Ståhl, S.; Frejd, F.Y.; Orlova, A. Affibody molecules for epidermal growth factor receptor targeting in vivo. aspects of dimerization and labeling chemistry. J. Nucl. Med. 2009, 50(2), 274-283.
47. 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J. Nucl. Med. 2009, 50(3),417-425.
48. 111In-benzyl-DTPAZHER2: 342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J. Nucl. Med. 2006, 47(5), 846-853.
49. 111/114mIn]CHX-A''-DTPAZHER2: 342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors. Q. J. Nucl. Med. Mol. Imaging, 2007, 51(4), 314-323.
50. Orlova, A.; Tran, T.; Widström, C.; Engfeldt, T.; Eriksson Karlström, A.; Tolmachev, V. Pre-clinical evaluation of [111In]-benzyl-DOTA-ZHER2:342, a potential agent for imaging of HER2 expression in malignant tumors. Int. J. Mol. Med., 2007, 20, 397-404.
51. Valkema, R.; De Jong, M.; Bakker, W.H.; Breeman, W.A.; Kooij, P.P.; Lugtenburg, P.J.; De Jong, F.H.; Christiansen, A.; Kam, B.L.; De Herder, W.W.; Stridsberg, M.; Lindemans, J.; Ensing, G.; Krenning, E.P. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin. Nucl. Med. 2002, 32(2),110-122.
52. Kwekkeboom, D.J.; Mueller-Brand, J.; Paganelli, G.; Anthony, L.B.; Pauwels, S.; Kvols, L.K.; O'dorisio, T.M.; Valkema, R.; Bodei, L.; Chinol, M.; Maecke, H.R.; Krenning, E.P. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J. Nucl. Med. 2005, 46(Suppl 1), 62S-66S.
53. Engfeldt, T.; Renberg, B.; Brumer, H.; Nygren, P.A.; Karlström, A.E. Chemical synthesis of triple-labelled three-helix bundle bind ing proteins for specific fluorescent detection of unlabelled protein. ChemBioChem, 2005, 6(6), 1043-1050.
54. Orlova, A.; Tolmachev, V.; Pehrson, R.; Lindborg, M.; Tran, T.; Sandström, M.; Nilsson, F.Y.; Wennborg, A.; Abrahmsén, L.; Feldwisch, J. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007, 67(5),2178-2186.
55. 111In-labelled analogue. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37(7), 1356-1367.
56. Baum, R.P.; Prasad, V.; Müller, D.; Schuchardt, C.; Orlova, A.; Wennborg, A.; Tolmachev, V.; Feldwisch J. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules. J. Nucl. Med. 2010 In press.
57. Webster, J.M.; Zhang, R.; Gambhir, S.S.; Cheng, Z.; Syud, F.A. Engineered two-helix small proteins for molecular recognition. ChemBioChem. 2009, 10(8),1293-1296.
58. Ren, G.; Zhang, R.; Liu, Z.; Webster, J.M.; Miao, Z.; Gambhir, S.S.; Syud, F.A.; Cheng, Z. A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression. J. Nucl. Med. 2009, 50(9),1492-1499.
59. 99mTcchelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur. J. Nucl. Med. Mol. Imaging. 2007, 34(5), 722-733.
60. Engfeldt, T.; Tran, T.; Orlova, A.; Widström, C.; Feldwisch, J.; Abrahmsen, L.; Wennborg, A., Karlström, A.E.; Tolmachev, V. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur. J. Nucl. Med. Mol. Imaging. 2007, 34(11), 1843-1853.
61. Tran, T.; Engfeldt, T.; Orlova, A.; Sandström, M.; Feldwisch, J.; Abrahmsén, L.; Wennborg, A.; Tolmachev, V.; Karlström, A.E. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug. Chem. 2007, 18(6), 1956-1964.
62. 99mTc-labelled Affibody molecules with reduced renal uptake. Eur. J. Nucl. Med. Mol. Imaging. 2008, 35(12), 2245-2255.
63. Tran, T.A.; Ekblad, T.; Orlova, A.; Sandström, M.; Feldwisch, J.; Wennborg, A.; Abrahmsén, L.; Tolmachev. V.; Eriksson Karlström, A. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. Bioconjug. Chem. 2008, 19(12), 2568-2576.
64. 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules. Bioorg. Med. Chem. Lett. 2009, 19(14), 3912-2914.
65. Mume, E.; Orlova, A.; Larsson, B.; Nilsson, A.S.; Nilsson, F.Y.; Sjöberg, S.; Tolmachev, V. Evaluation of (4-hydroxyphenyl) ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug. Chem. 2005, 16(6),1547-1555.
66. Kramer-Marek, G.; Kiesewetter, D.O.; Martiniova, L.; Jagoda, E.; Lee, S.B.; Capala, J. [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging. 2008, 35(5), 1008-1018.
67. Kiesewetter, D.O.; Krämer-Marek, G.; Ma, Y.;Capala J. Radiolabeling of HER2 specific Affibody(R) molecule with F-18. J. Fluor. Chem. 2008, 129(9), 799-805.
68. Kramer-Marek, G.; Kiesewetter, D.O.; Capala, J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J. Nucl. Med. 2009, 50(7), 1131-1139.
69. Namavari, M.; Padilla De Jesus, O.; Cheng, Z.; De, A.; Kovacs, E.; Levi, J.; Zhang, R.; Hoerner, J.K.; Grade, H.; Syud, F.A.; Gambhir, S.S. Direct site-specific radiolabeling of an Affibody protein with 4-[18F]fluorobenzaldehyde via oxime chemistry. Mol. Imaging. Biol. 2008, 10(4), 177-181
70. Ahlgren, S.; Orlova, A.; Rosik, D.; Sandström, M.; Sjöberg, A.; Baastrup, B.; Widmark, O.; Fant, G.; Feldwisch, J.; Tolmachev, V. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug. Chem., 2008, 19(1),235-243.
71. Wållberg, H.; Ahlgren, S.; Widström, C.; Orlova, A. Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395(-Cys) affibody molecule for targeting of HER2-expressing tumors. Mol. Imaging Biol. 2010, 12(1),54-62.
72. Anderson, C.J.; Wadas, T.J.; Wong, E.H.; Weisman, G.R. Crossbridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(2),185-192.
73. Tolmachev, V.; Xu, H.; Wållberg, H.; Ahlgren, S.; Hjertman, M.; Sjöberg, A.; Sandström, M.; Abrahmsén, L.; Brechbiel, M.W.; Orlova, A. Evaluation of a maleimido derivative of CHX-A DTPA for site-specific labeling of affibody molecules. Bioconjug. Chem. 2008, 19(8), 1579-1587.
74. 99mTc to tumor-targeting Affibody molecules. Bioconjug. Chem. 2007, 18(2), 549-558.
75. Ahlgren, S.; Wållberg, H.; Tran, T.A.; Widström, C.; Hjertman, M.; Abrahmsén, L.; Berndorff, D.; Dinkelborg, L.M.; Cyr, J.E.; Feldwisch, J.; Orlova, A.; Tolmachev, V. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J. Nucl. Med. 2009, 50(5), 781-789.
76. 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine. Nucl. Med. Biol., 2010 In press.
77. Tran, T.A.; Rosik, D.; Abrahmsén, L.; Sandström, M.; Sjöberg, A.; Wållberg, H.; Ahlgren, S.; Orlova, A.; Tolmachev, V. Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. Eur. J. Nucl. Med. Mol. Imaging. 2009, 36(11), 1864-1873 {78] Castillo, L.; Etienne-Grimaldi, M.C.; Fischel, J.L.; Formento, P.; Magné, N.; Milano, G. Pharmacological background of EGFR targeting. Ann. Oncol. 2004, 15(7),1007-1012.
78. Castillo, L.; Etienne-Grimaldi, M.C.; Fischel, J.L.; Formento, P.; Magné, N.; Milano, G. Pharmacological background of EGFR targeting. Ann. Oncol. 2004, 15(7),1007-1012.
79. Nordberg, E.; Friedman, M.; Göstring, L.; Adams, G.P.; Brismar, H.; Nilsson, F.Y.,; Ståh, l S.; Glimelius, B.; Carlsson. J. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl. Med. Biol. 2007, 34(6),609-618.
80. Nordberg, E.; Orlova, A.; Friedman, M.; Tolmachev. V.; Ståhl, S.; Nilsson, F.Y.; Glimelius, B.; Carlsson, J. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol. Rep., 2008, 19(4), 853-857.
81. Friedman, M.; Orlova, A.; Johansson, E.; Eriksson, T.L.; Höidén-Guthenberg, I.; Tolmachev, V.; Nilsson, F.Y.; Ståhl, S. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J. Mol. Biol. 2008, 376(5),1388-1402.
82. Tolmachev, V.; Orlova, A.; Wei, Q.; Bruskin, A.; Carlsson, J.; Gedda. L. Comparative biodistribution of potential antiglioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice. Cancer. Biother. Radiopharm. 2004, 19 (4), 491-501.
83. Velikyan, I.; Sundberg, A.L.; Lindhe, O.; Höglund, A.U.; Eriksson, O.; Werner, E.; Carlsson, J.; Bergström, M.; Långström, B.; Tolmachev, V. Preparation and evaluation of (68)Ga-DOTAhEGF for visualization of EGFR expression in malignant tumors. J. Nucl. Med. 2005, 46(11),1881-1888.
84. Tolmachev. V.; Rosik, D.; Wållberg, H.; Sjöberg, A.; Sandström, M.; Hansson, M.; Wennborg, A.; Orlova, A. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR (111)In-DOTA-Z (EGFR:2377) Affibody molecule: aspect of the injected tracer amount. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37(3), 613-622.